Author: Ravi Shankar

As part of the implementation of Bang & Olufsen A/S’ long-term share-based incentive programs certain members of management have acquired shares in Bang & Olufsen A/S vested under the programs. In that connection, Bang & Olufsen A/S has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in Bang & Olufsen made by persons discharging managerial responsibilities in Bang & Olufsen A/S and/or persons closely related with them.

Please see attached file for details.

For further information, please contact: Sr. Director, Strategy & Investor Relations, Cristina Rønde Hefting, phone: +45 4153 7303.

Attachment

• BO_2618_PDMR Announcement (vesting of shares)_Nikolaj Wendelboe

InstaMortgage reported approximately $4.5 million in revenue and $3.3 million in gross profit for the six months ended June 30, 2026, while reporting positive net income

Unaudited pro forma combined revenue was approximately $6.4 million for the six months ended June 30, 2026, and approximately $11.8 million for the year ended December 31, 2025

DUBLIN, Ohio, Sept. 23, 2026 (GLOBE NEWSWIRE) — reAlpha Tech Corp. (Nasdaq: AIRE) (the “Company” or “reAlpha”), an AI-powered real estate technology company, today announced financial and operating results for InstaMortgage Inc. (“InstaMortgage”) and unaudited pro forma combined financial information following the completion of its acquisition of InstaMortgage.

InstaMortgage Standalone Financial Performance

InstaMortgage was acquired by reAlpha with an established operating business that generated revenue, gross profit and positive net income in 2025, while remaining profitable through the second quarter of 2026.

For the year ended December 31, 2025, InstaMortgage:

• Generated approximately $7.3 million in revenue;
• Generated approximately $5.3 million in gross profit;
• Reported approximately $0.1 million in net income; and
• Originated approximately $277.1 million in residential mortgage loan volume.

For the six months ended June 30, 2026, InstaMortgage:

• Generated approximately $4.5 million in revenue;
• Generated approximately $3.3 million in gross profit;
• Reported approximately $0.2 million in net income; and
• Originated approximately $177.0 million in residential mortgage loan volume.

As of June 30, 2026, InstaMortgage has originated more than $3.5 billion in residential mortgage loans since 2015, supported by a full-cycle lending operation spanning origination, underwriting, funding and loan sale.

“We believe that InstaMortgage meaningfully strengthens reAlpha’s financial and operating foundation and demonstrates what we are looking to build through our acquisition strategy,” said Thomas Kutzman, Chief Financial Officer of reAlpha. “On a pro forma basis, the acquisition increases our 2025 revenue by approximately 162% and gross profit by approximately 215%, while adding a direct-lending business that generated positive net income in 2025 while remaining profitable through the first six months of 2026. We are adding scale, but we are also adding capabilities and transaction economics that fit directly into the platform we have been building.”

Kutzman continued, “We are now operating at a larger scale, with a broader base of loan officers, which we believe provide opportunities to identify potential operational synergies and cost efficiencies over time. The expansion in the number of states in which we offer both real estate and mortgage services could create opportunities for revenue synergies by serving customers in these markets with multiple services over the course of a given transaction.”

Unaudited Pro Forma Combined Financial Information

For the six months ended June 30, 2026, reAlpha and InstaMortgage would have had approximately $6.4 million in unaudited pro forma combined revenue and approximately $4.6 million in unaudited pro forma combined gross profit.

For comparison, reAlpha reported approximately $2.0 million in standalone revenue and approximately $1.3 million in standalone gross profit for the same six-month period.

For the year ended December 31, 2025, reAlpha and InstaMortgage would have had approximately $11.8 million in unaudited pro forma combined revenue and approximately $7.7 million in unaudited pro forma combined gross profit.

For comparison, reAlpha reported approximately $4.5 million in standalone revenue and approximately $2.5 million in standalone gross profit for fiscal 2025. Accordingly, the unaudited pro forma combined figures represent approximately 2.6 times reAlpha’s reported standalone revenue and 3.2 times its reported standalone gross profit for the period.

The unaudited pro forma combined financial information was prepared in accordance with Article 11 of Regulation S-X. For purposes of the statements of operations, the financial information gives effect to the acquisition as if it had occurred on January 1, 2025 and is presented for informational purposes only.

The unaudited pro forma financial information is not necessarily indicative of consolidated results of operations of the combined business had the acquisition occurred at the beginning of the respective period, nor is it necessarily indicative of future results of operations of the combined company. The unaudited pro forma financial information is based on various assumptions and estimates and should be read in conjunction with the full set of pro forma financial information and the accompanying notes, as presented in Amendment No.1 to the Company’s Current Report on Form 8-K/A that will be filed with the Securities and Exchange Commission (the “SEC”) on September 23, 2026.

About reAlpha Tech Corp.

reAlpha Tech Corp. (Nasdaq: AIRE) is an AI-powered real estate technology company that aims to transform the multi-trillion-dollar U.S. real estate services market. reAlpha is developing an end-to-end platform that streamlines real estate transactions through integrated brokerage, mortgage, and title services. With a strategic, acquisition-driven growth model and proprietary AI infrastructure, reAlpha is building a vertically integrated ecosystem designed to deliver a simpler, smarter, and more affordable path to homeownership. For more information, visit www.realpha.com.

About InstaMortgage Inc.

Originally founded in 2008 by Shashank Shekhar as Arcus Lending, the company rebranded as InstaMortgage, NMLS 1035734, in 2021. InstaMortgage aims to provide a different mortgage experience to its clients across 29 states and Washington D.C. By combining technology with expert advice, excellent customer service, and competitive rates, InstaMortgage delivers mortgage options that are tailored to each client’s unique financial situation. To learn more, visit www.instamortgage.com.

Forward-Looking Statements        

The information in this press release includes “forward-looking statements.” Any statements other than statements of historical fact contained herein, including statements by reAlpha’s Chief Financial Officer, Thomas Kutzman, or statements about the InstaMortgage acquisition, the anticipated benefits of the InstaMortgage acquisition, reAlpha’s ability to integrate InstaMortgage into its business and scale its business following the acquisition of InstaMortgage, reAlpha’s long-term platform strategy and anticipated benefits to customers, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: reAlpha and InstaMortgage’s ability to obtain regulatory approval in Virginia and New York; reAlpha’s ability to realize the expected benefits of the acquisition of InstaMortgage and its operations, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the potential negative effects of the Company’s and InstaMortgage’s business from not obtaining the regulatory approvals in Virginia and New York timely or at all; the health of the U.S. residential real estate industry and changes in general economic conditions; reAlpha’s ability to pay contractual obligations, including with respect to the acquisition of InstaMortgage; reAlpha’s liquidity, operating performance, cash flow and ability to secure adequate financing; reAlpha’s ability to maintain compliance with Nasdaq’s continued listing rules; reAlpha’s ability to generate additional sales or revenue from having access to, or obtaining, additional U.S. states brokerage licenses; whether reAlpha’s technology and products will be accepted and adopted by its customers and intended users; reAlpha’s ability to integrate the business of its acquired companies into its existing business, including InstaMortgage, and the anticipated demand for such acquired companies’ services; reAlpha’s ability to successfully enter new geographic markets and to scale its operational capabilities to expand into additional geographic markets and nationally; the potential loss of key employees of reAlpha and of its subsidiaries; reAlpha’s ability to obtain, and maintain, the required licenses to operate in the U.S. states in which it, or its subsidiaries, operate in, or intend to operate in; reAlpha’s ability to maintain and strengthen its brand and reputation; reAlpha’s ability to continue attracting loan officers and maintain its relationship with its REALTOR® affiliate to expand its operations nationally; the availability of rebates, which may be limited or restricted by state law; risks related to data privacy, including evolving laws and consumer expectations; the inability to accurately forecast demand for AI-based real estate-focused products; the inability to execute business objectives and growth strategies successfully or sustain reAlpha’s growth; the inability of reAlpha’s customers to pay for reAlpha’s services; reAlpha’s ability to obtain additional financing or access the capital markets on acceptable terms and conditions in the future; changes in applicable laws or regulations, including with respect to the real estate market, AI and AI technologies, and the impact of the regulatory environment and complexities with compliance related to such environment; reAlpha’s ability to effectively compete in the real estate and AI industries; and other risks and uncertainties indicated in reAlpha’s most recent Annual report on Form 10-K and current or periodic reports filed with the SEC and available for review at www.sec.gov. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. Although reAlpha believes that the expectations reflected in the forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. reAlpha’s future results, level of activity, performance or achievements may differ materially from those contemplated, expressed or implied by the forward-looking statements, and there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking statements. For more information about the factors that could cause such differences, please refer to reAlpha’s filings with the SEC. Readers are cautioned not to put undue reliance on forward-looking statements, and reAlpha does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Media Contact:

Payton Cuddy, Senior Marketing Manager
media@realpha.com

Investor Relations Contact:

Adele Carey, VP of Investor Relations
InvestorRelations@reAlpha.com

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing technologies, is pleased to announce the deployment of its BreathLogix alcohol screening solution at a manufacturing facility located in Alabama. The deployment marks the first delivery of the BreathLogix solution to a U.S.-based manufacturing company.

The deployment supports the customer’s workplace safety and impairment prevention program by providing automated alcohol screening for employees in safety-sensitive work environments. The customer is a leading industrial printing and manufacturing organization serving businesses across North America.

BreathLogix will be used to facilitate routine employee alcohol screening as part of the facility’s safety and compliance initiatives. The system is designed to help employers identify alcohol-related impairment risks, strengthen workplace safety protocols, and support a safe working environment for employees, contractors, and visitors. The deployment is being facilitated by AlcoPro, Inc., an authorized reseller (alcopro.com).

BreathLogix rapidly screens for alcohol using a breath sample while simultaneously capturing a photograph of the user for identity verification. The system provides precise Blood Alcohol Content (BAC / BrAC) readings and can automatically deliver alerts via SMS and email to designated managers when positive results are detected.

The deployment reflects first delivery of the BreathLogix solution with a manufacturing company in the U.S. BreathLogix can meet the needs of employers seeking modern, automated screening technologies that can improve operational efficiency while supporting occupational health and safety objectives. Manufacturing facilities, logistics operations, transportation organizations, and other safety-sensitive workplaces are increasingly adopting alcohol screening programs as part of broader workforce risk management strategies.

“This deployment demonstrates the expanding application of BreathLogix within industrial and manufacturing environments,” stated Rav Mlait, Chief Executive Officer of Cannabix Technologies. “Employers continue to seek practical tools that can help reduce impairment-related risks, improve workplace safety, and support compliance with corporate safety policies. BreathLogix is designed to provide a simple and efficient screening solution that helps organizations proactively manage these challenges.”

Figure 1. BreathLogix Alcohol Screening Device Image

BreathLogix supports a broad range of alcohol screening applications, including:

• Workplace and safety-sensitive employee screening
• Manufacturing and industrial operations
• Transportation and logistics workforces
• Return-to-work and fitness-for-duty assessments
• Contractor and visitor screening programs
• Construction and infrastructure projects
• Random and scheduled alcohol testing
• Corporate health and safety initiatives

By enabling reliable and automated alcohol screening, BreathLogix helps organizations strengthen workplace safety programs, reduce impairment-related risks, improve compliance oversight, and promote a culture of accountability.

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leading developer of breath-based technologies designed to enhance public safety and reduce impairment-related risks in a range of different settings. The Marijuana Breath Test (MBT) targets delta-9 THC—the primary psychoactive compound in cannabis—in breath, providing a practical solution for identifying recent marijuana use.

The BreathLogix, unmanned alcohol screening solution supports organizations in proactively monitoring alcohol impairment, strengthening safety protocols, and promoting responsible behavior. By delivering innovative, non-invasive screening tools, Cannabix aims to help reduce accidents, improve decision-making, and protect organizations, individuals and the public at large. Visit www.cannabixtechnologies.com

We seek Safe Harbor.  
 On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains certain “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements are often identified by words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “may,” “will,” “could,” “should,” “potential,” and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements regarding: the anticipated benefits, capabilities, reliability, performance and adoption of the Company’s BreathLogix alcohol screening solution; the expected use of BreathLogix by manufacturing companies, industrial employers, transportation organizations and other safety-sensitive workplaces; the Company’s ability to expand commercial deployments of BreathLogix in the United States and other jurisdictions; the potential for recurring revenue from product sales, service agreements, software offerings and related programs; the commercialization, market acceptance and adoption of the Company’s technologies; the Company’s ability to enter into additional customer, reseller, distribution, service or strategic partnership agreements; and the Company’s ongoing business, product development, regulatory, operational and financing plans. Forward-looking statements are based on management’s current expectations, assumptions and beliefs and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. Such factors include, without limitation: the ability of the Company to successfully manufacture, deploy, support and maintain its technologies; customer acceptance, utilization and retention; the ability to secure additional commercial customers and distribution relationships; regulatory developments; changes in workplace safety, employment or privacy laws; competitive developments; technological advancements by competitors; economic, industry and market conditions; supply chain disruptions; the availability of financing; and other risks detailed from time to time in the Company’s public disclosure documents. There can be no assurance that the Company’s products will achieve widespread commercial acceptance, that existing deployments will result in additional contracts, recurring revenues or market expansion, or that any anticipated business objectives, strategic initiatives, partnerships or growth opportunities will be realized. Actual results may differ materially from those currently anticipated in such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and are based on the beliefs, estimates, expectations and opinions of management on the date such statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8814b7b4-4011-4068-9441-88f557ab5f3e

Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108

Primary efficacy results from approximately 204 patients with moderately to severely active ulcerative colitis expected in the second half of 2027

Denver, CO, Sept. 23, 2026 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that Health Canada has cleared the Company’s Clinical Trial Application (CTA) for ASCENTRA-UC, its global Phase 2 study evaluating PALI-2108 in patients with moderately to severely active ulcerative colitis (UC).

The clearance enables Palisade to advance clinical trial activities in Canada, expanding the study’s geographic reach and supporting planned enrollment. Together with prior regulatory clearance in the United States, this milestone advances the Company’s global site activation and enrollment strategy. Primary efficacy results from the study’s 12-week induction period are expected in the second half of 2027.

“Health Canada clearance represents another important execution milestone as we advance ASCENTRA-UC globally,” said JD Finley, Chief Executive Officer of Palisade Bio. “Our focus is on efficiently activating sites, expanding patient access to the study and delivering the clinical data needed to define PALI-2108’s potential in ulcerative colitis. We remain on track to begin patient dosing in the second half of 2026, with primary efficacy results expected in the second half of 2027.”

ASCENTRA-UC is a global, multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase 2 trial designed to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of PALI-2108 in patients with moderately to severely active UC. The study is expected to enroll approximately 204 patients and will evaluate once-daily 15 mg and 30 mg doses of PALI-2108 compared with placebo.

The primary endpoint is clinical remission at Week 12, as measured by the modified Mayo Score. Key secondary endpoints include clinical response, endoscopic improvement and histologic-endoscopic mucosal improvement. The study also includes a 36-week maintenance phase extension designed to evaluate durability of response and longer-term safety through Week 48.

“PALI-2108 is designed to combine the convenience of once-daily oral dosing with targeted activation in the terminal ileum and colon,” said Mitch Jones, M.D., Ph.D., President and Chief Medical Officer of Palisade Bio. “ASCENTRA-UC builds on the clinical and pharmacologic findings observed to date and will rigorously evaluate whether this approach can translate into clinical remission and mucosal improvement. Expanding the study into Canada supports enrollment and brings us closer to answering these important clinical questions.”

About PALI-2108

PALI-2108 is a once-daily oral PDE4 inhibitor prodrug designed for targeted activation in the terminal ileum and colon. Across Phase 1 studies in healthy volunteers and patients with ulcerative colitis and fibrostenotic Crohn’s disease, PALI-2108 demonstrated favorable safety and tolerability, differentiated pharmacokinetics and sustained PDE4 inhibition above IC90, supporting advancement into Phase 2 development.

About Palisade Bio

Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company developing prodrugs for patients living with inflammatory and fibrotic diseases.

The Company’s lead clinical product candidate, PALI-2108, is being advanced into Phase 2 clinical trials as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). Despite the availability of multiple biologic and small-molecule therapies, many patients with UC and CD do not achieve durable remission, lose response over time, or discontinue treatment because of safety or tolerability limitations. The Company believes PALI-2108 has the potential to address these limitations through once-daily oral dosing, targeted lower-intestinal bioactivation and broad PDE4-mediated anti-inflammatory activity.

For more information, please go to www.palisadebio.com.

Forward Looking Statements

Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: implied or express statements regarding the pharmacological properties, safety, tolerability, clinical response and efficacy, and therapeutic potential of PALI-2108, dosing levels and timing of key PALI-2108 development milestones such as regulatory submissions and approvals, trial enrollments and commencements and efficacy readouts, and the Company’s expected cash runway. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the Company’s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, clinical response and efficacy, dosing or durability of effect, observed from preclinical or clinical trials with a limited number of patients, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2026, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law.

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com

Company Advances Development of First U.S. AI Infrastructure Hub,
Executes Its Quantum & AI Systems Strategy

ITASCA, Ill., Sept. 23, 2026 (GLOBE NEWSWIRE) — Quanome Technologies, Inc. (Nasdaq: QNME) (“Quanome” or the “Company”) is advancing its Quantum and AI Systems business through an approximately US$18.8 million purchase agreement for computing infrastructure powered by NVIDIA GPU technology to build its AI cloud business through its subsidiary, XDT Infrastructure I, LLC (“XDT”). The Company entered into the agreement on September 16, 2026, representing an initial step in executing Quanome’s strategy and its planned phased development of XDT.

Through XDT, Quanome aims to give businesses managed access to AI computing capacity to support their development and expansion. Once operational, clients will be able to develop and run AI applications, process complex data and scale their computing capacity without building and managing their own infrastructure. These capabilities are designed to support faster product development, automation and improved business productivity. For Quanome, XDT offers the potential to build recurring revenue from computing services, with further investment intended to align with customer demand, available funding and operational readiness.

Demand for AI computing services is expanding as businesses integrate AI into their operations. The U.S. Census Bureau reported that 17% to 20% of U.S. businesses used AI between December 2025 and May 2026, while 20% to 23% expected to use it in the following six months. This adoption trend reinforces the importance of scalable computing capacity for businesses seeking to develop and deploy AI applications.

Yang Li, Chief Executive Officer of Quanome Technologies, said: “This investment puts Quanome’s commitment to quantum and AI into action. Through XDT, we aim to give more businesses access to advanced AI computing to power their growth. Our priorities are clear: launch our first hub, grow a strong client base and build recurring revenue to deliver long-term shareholder value.”

XDT sits within Quanome’s Quantum and AI Systems strategic stream, alongside the Group’s three other areas of focus: Quantum Life Sciences – Molecular Discovery, Advanced Nuclear, and Quantum-Safe Cybersecurity. It supports Quanome’s broader objective of translating scientific and technological advances into practical applications that enhance industrial productivity and support economic development.

Quanome expects its first U.S. AI infrastructure hub to be operational from Q4 2026, subject to delivery and deployment.

ENDS

Media / Investor Contact
investor@quanometech.com
www.quanometech.com / www.xdt.com

Editors Notes

About Quanome Technologies

Quanome Technologies, Inc. (Nasdaq: QNME) focuses on opportunities across Quantum and AI Systems, Quantum Life Sciences – Molecular Discovery, Advanced Nuclear, and Quantum-Safe Cybersecurity. The Company combines commercial initiatives with the development of a global scientific network through its Global Quantum Council and Scientific Advisory Network. Through its subsidiary “XDT” (XDT Infrastructure I, LLC), Quanome is building an AI cloud business to broaden access to advanced computing resources. www.quanometech.com / www.xdt.com

Forward-Looking Statements

This release contains forward-looking statements regarding the purchase, delivery, deployment and utilization of GPU servers; the expected commencement of operations in Q4 2026; the development and expansion of XDT; and anticipated customer benefits and revenue opportunities. These statements are based on current plans, assumptions and expectations and involve risks and uncertainties. Actual results and timing may differ materially due to financing availability, customer demand, supplier performance, production and delivery conditions, regulatory requirements, technical and operational matters, third-party performance and other transaction conditions. There can be no assurance that the purchase or deployment will be completed as contemplated, that operations will begin on the expected schedule, or that the intended commercial benefits will be achieved. Additional risks are described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements except as required by applicable law.

Allowance extends the Company’s patent family covering gesture and proportional-control interaction with digital devices, from consumer electronics and XR to emerging applications in robotics and physical AI

YOKNEAM ILLIT, ISRAEL, Sept. 23, 2026 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) (“Wearable Devices” or the “Company”), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, today announced a Notice of Allowance from the China National Intellectual Property Administration (“CNIPA”) for its patent application.

The allowed application, titled “Method and Apparatus for a Gesture Controlled Interface for Wearable Devices,” extends a U.S.-granted intellectual property (“IP”) family covering a wrist-worn band that senses surface nerve conduction signals, the Company’s term for surface electromyography (“EMG”)-class bio-potentials, and turns hand and finger movement into commands without cameras, controllers or touchscreens. The China allowance specifically protects the Company’s technological ability to measure the intensity of a gesture – not just whether fingers were pressed together, but how firmly. This distinction converts a simple on/off motion into smooth, continuous, pressure-based control, much like a dimmer rather than a standard light switch.

The Company sees this capability supporting a broad set of applications across its target markets:

• Consumer electronics, extended reality (“XR”) products, and smart glasses – Intuitive, touchless micro-gesture control, navigation, and interaction with digital overlays from the wrist.
• Robotics and physical AI – An emerging area in which capturing the force and motion an individual applies may help robots learn physical tasks from human demonstration. Because the sensing takes place at the user’s wrist, an individual can be recorded working bare-handed and naturally, without instrumented gloves or force-sensing rigs that alter the way an object is handled.
• Accessibility and healthcare – Device control for users with limited mobility and objective measurements of grip strength and rehabilitation progress which can assist users in daily life as well as in clinics.

“Human intent is grounded in physiology – you can’t scrape it from the internet,” said Guy Wagner, Chief Scientific Officer and co-founder of Wearable Devices. “It lives in the body’s own signals: not just that someone picked something up, but how carefully they held it. That kind of nuance is what makes everyday device control feel natural, and it is also what newer fields such as physical AI will need as machines learn from people. We believe that securing this protection in China – the world’s largest developer, manufacturer and market for robotics and consumer electronics – is an important step for our IP portfolio.”

This allowance sits within a broader IP portfolio that now comprises 14 patent matters across the United States, China, and South Korea, six of which have been granted. With priority dates as early as 2015, this protection runs as late as 2043. Alongside its registered MUDRA trademark, the Company continues to pursue protection across major markets as part of a long-standing IP strategy supporting future licensing and partnership opportunities.

About Wearable Devices Ltd.

Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) is a growth company pioneering human-computer interaction through its AI-powered neural input touchless technology. Leveraging proprietary sensors, software, and advanced AI algorithms, the Company’s product offerings, including the Mudra Band, Mudra Link, and Mudra Pro, are defining the neural input category both for wrist-worn devices and for brain-computer interfaces. These products enable touch-free, intuitive control of digital devices using gestures across multiple operating systems.

Operating through a dual-channel model of direct-to-consumer sales and enterprise licensing and collaborations, Wearable Devices empowers consumers with stylish, functional wearables for enhanced experiences in gaming, productivity, and XR. In the business sector, the Company provides enterprise partners with advanced input solutions for immersive and interactive environments, from augmented reality/virtual reality/XR to smart environments. By setting the standard for neural input in the XR ecosystem, Wearable Devices is shaping the future of seamless, natural user experiences across some of the world’s fastest-growing tech markets. The ai6 Labs ecosystem accelerates this vision by integrating research, products, and AI breakthroughs. Expanding into Physical AI, the Company’s wearable neural sensing layer enriches human-generated training data for robotics and advanced physical systems.

Wearable Devices’ ordinary shares and warrants trade on the Nasdaq Capital Market under the symbols “WLDS” and “WLDSW,” respectively.

Forward-Looking Statements Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, we are using forward-looking statements when we discuss the expected benefits of the allowed patent application, the potential applications of the Company’s technology, that the patent allowance marks an important step in the Company’s IP portfolio, and the Company’s future growth and market opportunities, including potential future licensing and partnership opportunities. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the trading of our ordinary shares or warrants and the development of a liquid trading market; our ability to successfully market our products and services; the acceptance of our products and services by customers; our continued ability to pay operating costs and ability to meet demand for our products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; our ability to successfully develop new products and services; our success establishing and maintaining collaborative alliance agreements, licensing and supplier arrangements; our ability to comply with applicable regulations; and the other risks and uncertainties described in our annual report on Form 20-F for the year ended December 31, 2025, filed on March 12, 2026 and our other filings with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contact:

Michal Efraty
IR@wearabledevices.co.il

Phase III advances development of a modular, reusable, swarm based, precision-strike capability designed for U.S. Special Operations Forces, powered by XTEND’s operating system, XOS.

TAMPA, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) — XTEND AI Robotics, Inc. (NYSE: XTND), a leader in software systems and Physical AI, today announced that it has been awarded Phase III of the U.S. Special Operations Command (USSOCOM) Modular Kinetic Lethal Drone (MKLD) program, advancing the Company’s continued work in precision-strike unmanned systems for U.S. Special Operations Forces. The award is separate from, and follows, XTEND’s recent selection as a top performer in the Close-Quarters Battle segment of Gauntlet II under the U.S. Department of War’s Drone Dominance Program.

The MKLD solution brings together XTEND’s Striker, Scorpio 500 and Scorpio 1000 platforms with a common Ground Control Station and XTEND’s XOS operating system. The program is designed to provide small tactical units with modular, recoverable and reusable precision-strike capabilities across indoor, confined-space, urban and outdoor operational environments.

“Phase III is an important milestone in our continued work with the U.S. Special Operations community,” said Aviv Shapira, CEO and Co-Founder of XTEND. “Our focus is on giving Warfighters adaptable robotic capabilities that extend their reach and effectiveness while shifting risk from the operator to unmanned systems.”

Phase III builds on previous USSOCOM investment, development, testing and operational feedback and will further mature the MKLD capability.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the capabilities of XOS and the MKLD solution, the anticipated development and maturation of the MKLD capability under Phase III and XTEND’s financial prospects, including that according to the Drone Dominance Program the 10 companies selected for Gauntlet II are finalists for prototype contracts and awards are not guaranteed. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially, including the timing and size of orders from government and defense customers, the availability of government funding, the risk that the MKLD program does not advance beyond Phase III or result in production orders, geopolitical and economic conditions in the United States and the other regions in which XTEND operates, and the other risks described under “Risk Factors” in the registration statement on Form S-4 filed with the SEC in connection with the business combination and in XTEND’s other filings with the SEC, available at www.sec.gov. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. XTEND does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by applicable law.

About XTEND AI Robotics, Inc.

XTEND AI Robotics, Inc. (the “Company”) operates under two distinct business strategies. Through its wholly owned subsidiary XTEND Reality Expansion Ltd. (“XTEND”), the Company develops and sells software and advanced robotic hardware solutions for high-threat, complex operational environments where human exposure carries significant risk. Powered by its proprietary XTEND Operating System (“XOS”), these solutions are designed to provide autonomy at the edge. Through its wholly owned subsidiary JFB Construction Holdings (“JFB”), the Company operates a commercial and residential real estate construction and development strategy, delivering services including retail corporate buildouts, multifamily developments and luxury residential homes. The Company was formed through the combination of XTEND and JFB, uniting two complementary businesses to pursue shared technology and market opportunities, including applying XTEND’s AI-enabled drone technology to jobsite security, land surveying, building inspections and monitoring on JFB’s real estate projects, and leveraging JFB’s construction expertise to help reduce the cost of XTEND’s U.S. manufacturing expansion.

Contacts

XTEND Media Contact:
Headline Media
Sarah Small
929-255-1449
sarah@headline.media

XTEND Investor Relations:
MZ North America
Shannon Devine
203-741-8811
XTND@mzgroup.us

Phase III advances development of a modular, reusable, swarm based, precision-strike capability designed for U.S. Special Operations Forces, powered by XTEND’s operating system, XOS.

TAMPA, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) — XTEND AI Robotics, Inc. (NYSE: XTND), a leader in software systems and Physical AI, today announced that it has been awarded Phase III of the U.S. Special Operations Command (USSOCOM) Modular Kinetic Lethal Drone (MKLD) program, advancing the Company’s continued work in precision-strike unmanned systems for U.S. Special Operations Forces. The award is separate from, and follows, XTEND’s recent selection as a top performer in the Close-Quarters Battle segment of Gauntlet II under the U.S. Department of War’s Drone Dominance Program.

The MKLD solution brings together XTEND’s Striker, Scorpio 500 and Scorpio 1000 platforms with a common Ground Control Station and XTEND’s XOS operating system. The program is designed to provide small tactical units with modular, recoverable and reusable precision-strike capabilities across indoor, confined-space, urban and outdoor operational environments.

“Phase III is an important milestone in our continued work with the U.S. Special Operations community,” said Aviv Shapira, CEO and Co-Founder of XTEND. “Our focus is on giving Warfighters adaptable robotic capabilities that extend their reach and effectiveness while shifting risk from the operator to unmanned systems.”

Phase III builds on previous USSOCOM investment, development, testing and operational feedback and will further mature the MKLD capability.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the capabilities of XOS and the MKLD solution, the anticipated development and maturation of the MKLD capability under Phase III and XTEND’s financial prospects, including that according to the Drone Dominance Program the 10 companies selected for Gauntlet II are finalists for prototype contracts and awards are not guaranteed. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially, including the timing and size of orders from government and defense customers, the availability of government funding, the risk that the MKLD program does not advance beyond Phase III or result in production orders, geopolitical and economic conditions in the United States and the other regions in which XTEND operates, and the other risks described under “Risk Factors” in the registration statement on Form S-4 filed with the SEC in connection with the business combination and in XTEND’s other filings with the SEC, available at www.sec.gov. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. XTEND does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by applicable law.

About XTEND AI Robotics, Inc.

XTEND AI Robotics, Inc. (the “Company”) operates under two distinct business strategies. Through its wholly owned subsidiary XTEND Reality Expansion Ltd. (“XTEND”), the Company develops and sells software and advanced robotic hardware solutions for high-threat, complex operational environments where human exposure carries significant risk. Powered by its proprietary XTEND Operating System (“XOS”), these solutions are designed to provide autonomy at the edge. Through its wholly owned subsidiary JFB Construction Holdings (“JFB”), the Company operates a commercial and residential real estate construction and development strategy, delivering services including retail corporate buildouts, multifamily developments and luxury residential homes. The Company was formed through the combination of XTEND and JFB, uniting two complementary businesses to pursue shared technology and market opportunities, including applying XTEND’s AI-enabled drone technology to jobsite security, land surveying, building inspections and monitoring on JFB’s real estate projects, and leveraging JFB’s construction expertise to help reduce the cost of XTEND’s U.S. manufacturing expansion.

Contacts

XTEND Media Contact:
Headline Media
Sarah Small
929-255-1449
sarah@headline.media

XTEND Investor Relations:
MZ North America
Shannon Devine
203-741-8811
XTND@mzgroup.us

The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders

TEL AVIV, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, highlighted the expansion of the U.S. intellectual property portfolio through its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND).

As part of the collaboration, three U.S. patent applications have been published covering novel combinations of lysergic acid diethylamide (“LSD”), ketamine and ibogaine with N-acylethanolamines, including palmitoylethanolamide (“PEA”), NeuroThera’s proprietary technology.

The applications cover potential therapeutic uses across a range of indications, including mental health disorders such as depression and post-traumatic stress disorder, as well as pain and substance use disorders.

These U.S. patent applications build on previously announced intellectual property generated through the collaboration, including a U.S. patent application covering the combination of MDMA and N-acylethanolamines for potential treatment of PTSD, anxiety and eating disorders.

The continued maturation of the patent portfolio reflects the broader potential applications of NeuroThera’s PEA technology when combined with psychoactive compounds such as psychedelic compounds. NeuroThera believes that these combinations may support the development of novel therapeutic approaches across multiple neuropsychiatric and substance use disorder indications.

NeuroThera and Clearmind continue to advance their collaboration, aimed at bringing safer and more effective treatments to market for some of the most common and rapidly growing mental‑health conditions. The companies remain focused on combining PEA with psychedelic‑derived compounds, while enhancing the intellectual property portfolio supporting these innovative therapeutic programs

About SciSparc Ltd. (Nasdaq: SPRC):

The Company, through its subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

About NeuroThera Labs Inc.

NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the potential therapeutic uses of NeuroThera’s product candidates across a range of indications, the broader potential applications of NeuroThera’s PEA technology, the potential of NeuroThera and Clearmind to bring safer and more effective treatments to market for some of the most common and rapidly growing mental‑health conditions, and continued enhancement of the intellectual property portfolio supporting these innovative therapeutics.

The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, as amended, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055

Latest prepayment continues Holley’s deleveraging trajectory for the last three years and reinforces the Company’s long-term goal to be at or below 3.0x leverage

NASHVILLE, Tenn., Sept. 23, 2026 (GLOBE NEWSWIRE) — Holley Performance Brands (NYSE: HLLY), a leader in automotive aftermarket performance solutions, today announced a voluntary prepayment of $10 million toward its term loan, reflecting the Company’s continued focus on balance sheet optimization and disciplined capital deployment.

Including this latest payment, Holley has repaid a total of $125 million of debt since September 2023, funded entirely through free cash flow generation. Since initiating this program, the Company has reduced its Total Leverage Ratio from a peak of 5.67x, remains on track to reach its previously communicated year-end target of below 3.5x, and continues to target a long-term leverage ratio of approximately 3.0x. Cumulatively, the $125 million in debt reductions generate approximately $5 million in annualized net interest savings.

“This latest prepayment reflects the discipline and consistency of our capital allocation approach,” said Jesse Weaver, Chief Financial Officer of Holley Performance Brands. “Since 2023, we have reduced our debt by $125 million, funded entirely by free cash flow, while continuing to invest in the business. That progress reflects our three-pronged capital allocation framework: reducing leverage, pursuing accretive M&A, and returning capital to shareholders opportunistically. We remain on track to bring year-end leverage below 3.5x, with a long-term target of approximately 3.0x, and we believe this continued financial discipline positions Holley to create long-term value for our shareholders.”

For more Holley company news, click here.

Forward-Looking Statements 
Certain statements in this press release may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995.  Such forward-looking statements are subject to risks, uncertainties, and other important factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including but not limited to Holley’s ability to achieve its stated leverage targets, opportunistically reduce debt, complete accretive acquisitions of complementary brands at attractive valuations, and opportunistically repurchase its own shares, and the other risks and uncertainties set forth in the Annual Report on Form 10-K for the year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 16, 2026, and in any subsequent filings with the SEC.

About Holley Performance Brands
Holley Performance Brands (NYSE: HLLY) is home to a portfolio of iconic brands that serve enthusiasts across the high-performance aftermarket. The company designs, engineers, manufactures and markets category-leading products and solutions for automotive enthusiasts through a focused portfolio spanning four consumer vertical groupings: American Performance, Modern Truck & Off-Road, Euro & Import, and Safety & Racing. For more than a century, Holley has built its reputation through innovation, technical expertise and a deep understanding of enthusiast culture. For more information, visit https://www.holley.com.

Investor Relations Contact(s):
Anthony Rozmus / Jenna Kozlowski
Solebury Strategic Communications
203-428-3224
Holley@soleburystrat.com

Media Relations Contact(s):
Nathan Espinosa/Michael Murray
Kahn Media
818-881-5246
Holley@KahnMedia.com